HCWB vs. TTOO, ENLV, LMNL, SGTX, CYAD, SCPH, VERU, RAPT, SYRS, and SGMT
Should you be buying HCW Biologics stock or one of its competitors? The main competitors of HCW Biologics include T2 Biosystems (TTOO), Enlivex Therapeutics (ENLV), Liminal BioSciences (LMNL), Sigilon Therapeutics (SGTX), Celyad Oncology (CYAD), scPharmaceuticals (SCPH), Veru (VERU), RAPT Therapeutics (RAPT), Syros Pharmaceuticals (SYRS), and Sagimet Biosciences (SGMT). These companies are all part of the "medical" sector.
HCW Biologics (NASDAQ:HCWB) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability.
In the previous week, HCW Biologics' average media sentiment score of 0.00 equaled T2 Biosystems'average media sentiment score.
3.0% of HCW Biologics shares are held by institutional investors. Comparatively, 23.2% of T2 Biosystems shares are held by institutional investors. 49.9% of HCW Biologics shares are held by company insiders. Comparatively, 0.1% of T2 Biosystems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
HCW Biologics has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500.
HCW Biologics has higher earnings, but lower revenue than T2 Biosystems.
T2 Biosystems received 400 more outperform votes than HCW Biologics when rated by MarketBeat users. However, 100.00% of users gave HCW Biologics an outperform vote while only 64.65% of users gave T2 Biosystems an outperform vote.
T2 Biosystems has a consensus price target of $3.00, suggesting a potential downside of 30.07%. Given T2 Biosystems' higher possible upside, analysts plainly believe T2 Biosystems is more favorable than HCW Biologics.
T2 Biosystems has a net margin of -636.09% compared to HCW Biologics' net margin of -697.53%. T2 Biosystems' return on equity of 0.00% beat HCW Biologics' return on equity.
Summary
HCW Biologics and T2 Biosystems tied by winning 6 of the 12 factors compared between the two stocks.
Get HCW Biologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCWB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCWB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HCW Biologics Competitors List
Related Companies and Tools
